RRM2B Antibody

1. The expression of p53R2 was associated closely with the development and progression of lung sarcomatoid carcinoma. PMID: 29246119
2. p53R2 protein is overexpressed in early-stage cervical cancer and unravels some unconventional oncogenic functions of p53R2. PMID: 28841361
3. High RRM2B expression is associated with neoplasms. PMID: 27004405
4. Studied the expression of ribonucleotide reductase (RR) subunit p53R2 in nasopharyngeal carcinoma and its significance in the prognosis. PMID: 29237424
5. RRM1/RRM2B enzyme is capable of retaining activity in hypoxia and therefore is favored over RRM1/RRM2 in order to preserve ongoing replication and avoid the accumulation of DNA damage in hypoxic cells. PMID: 28416140
6. A newly discovered role of E2F1 in the regulation of p53R2 expression in DNA damage response. PMID: 25312903
7. analysis of caspase-dependent degradation of human R2 and p53R2 small subunits PMID: 25878246
8. in Turkish population p53R2 genotype distributions between head and neck squamous epithelial cell cancer patients and control groups were not statistically significantly different. PMID: 24861915
9. Data indicate that forkhead transcription factorsF OXO3 directly bound to and transcriptionally activated the promoter of ribonucleotide reductase subunit RRM2B, and induced the expression of RRM2B at RNA and protein levels. PMID: 24947616
10. we found no support of the hypothesis that aberrations of RRM1 or RRM2B, neither individually nor in combination, are associated with an altered clinical outcome following chemotherapy. PMID: 24215511
11. Ribonucleotide reductase M2B inhibits cell migration and spreading by early growth response protein 1-mediated phosphatase and tensin homolog/Akt1 pathway in hepatocellular carcinoma. PMID: 24214128
12. RRM2B expression may discriminate cervical cancer phenotype and radiochemotherapy outcome PMID: 23552804
13. RRM2B is highly induced in a p53-dependent manner during senescence and is expressed at higher levels in senescent precancerous human prostatic intraepithelial neoplasm lesions compared to adjacent normal prostate glands. PMID: 23139867
14. p53R2 could regulate matrix synthesis via Akt phosphorylation during chondrocyte mechanotransduction. Down-regulation of p53R2 may be a new therapeutic approach in OA therapy. PMID: 22954457
15. p53R2 is directly regulated by p53 and also by a MEK2 (ERK kinase 2/MAP kinase kinase 2)-dependent pathway. PMID: 22895183
16. Propose p53R2 as a therapeutic target to enhance the effectiveness of chemotherapy in patients with p53R2-positive melanoma. PMID: 22902076
17. These results confirm a role for p53R2 in both Clofarabine and decitabine mechanism of action PMID: 22884950
18. In nontransformed cells only during quiescence, protein p53R2 is required for maintenance of mitochondrial DNA and for optimal DNA repair after ultraviolet damage. PMID: 22847445
19. Evidence that disease pathogenesis may be caused by defective RNR assembly is given. PMID: 21378381
20. Increased expression of p53R2 may predict gemcitabine resistance, and upregulated RNR activity may influence gemcitabine resistance in cholangiocarcinoma cells. PMID: 21451941
21. p53R2 may suppress cancer cell proliferation; plays critical roles not only in DNA damage repair but also in proliferation of cancer cells PMID: 21216934
22. p53R2 expression seems more important than that of hRRM2 in prognosis of early-stage lung cancer. PMID: 21965764
23. this study provides functional evidence that mitochondria is one of p53R2-targeted organelles and suggests an unexpected function of p53R2, which is beyond known ribonucleotide reductase function on dNTP synthesis, in mitochondrial homeostatic control. PMID: 21640705
24. Adult-onset progressive external ophthalmoplegia due to RRM2B mutations is associated with a benign myopathic phenotype and characterized by muscle-restricted, mitochondrial DNA deletions. PMID: 21646632
25. oss of p53R2 affects ribonucleotide reduction only in resting cells and leads to a decrease of dNTP catabolism by substrate cycles that counterweigh the loss of anabolic activity PMID: 21297166
26. This study correlates the distinct catalytic mechanisms of the small subunits hp53R2 and hRRM2 with a hydrogen-bonding network. PMID: 20484015
27. p53R2-dependent DNA synthesis plays a pivotal role in cell survival by repairing damaged DNA PMID: 11719458
28. Expression of p53R2, newly p53 target in oral normal epithelium, epithelial dysplasia and squamous cell carcinoma. PMID: 12565178
29. Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits. PMID: 12615712
30. UV-induced activation of p53R2 transcription and binding of p53R2 to hRRM1 to form RR holoenzyme are impaired in the p53-mutant cell line PC3. PMID: 14583450
31. Four regulatory-region variants were found, of which three were single nucleotide polymorphisms (SNPs) (nt 1 789 C/G, nt 1 928 A/G, 1 933 T/C), and one was 20 bp insertion which replaced a ATTTT between nt 1831 and 1835. PMID: 16127747
32. we developed a p53R2-dependent luciferase reporter gene assay, and demonstrated dose-dependent luminescence caused by adriamycin in two human cell lines that express wild-type p53, MCF-7 and HepG2 PMID: 16236544
33. RRM2 and p53R2 subunits share the same binding site on RRM1 PMID: 16376858
34. Expressions of p53 and p53R2 proteins should be useful for determining the tumor properties, including prognosis, in patients with esophageal squamous cell carcinoma. PMID: 16778101
35. Catalytic properties are assessed. PMID: 16846634
36. ectopic expression of human papillomavirus 16 E6 impaired p53R2 induction after DNA damage in human fibroblasts PMID: 16872707
37. Mutation of RRM2B is associated with mitochondrial Diseases PMID: 17486094
38. p53R2 expression is reduced after X-ray irradiation following the transfection of p53R2 siRNAin esophageal squamous cell carcinoma. This could potentially improve efficacy of radiotheraepy. PMID: 17671702
39. a protective function of the p53R2 ribonucleotide reductase subunit in prevention or repair of NO-mediated genotoxic injury. PMID: 18474260
40. Sequencing the RRM2B gene revealed three missense mutations and two single nucleotide deletions in exons 6, 8, and 9, confirming that RRM2B mutations are important causes of MDS. PMID: 18504129
41. analysis of the effects of p53R2 silencing on DNA damage in LNCaP cells PMID: 18505925
42. p53R2 constitutes a potential target for anticancer drugs as well as a diagnostic marker in cancer. PMID: 18760875
43. The redox property, structure, and function of hRRM2 and p53R2, are studied. PMID: 19082948
44. This report describes two brothers, both deceased in infancy, with severe depletion of mitochondrial DNA (mtDNA) in muscle tissue. A novel missense mutation in the RRM2B gene, encoding the p53R2 subunit, was identified PMID: 19138848
45. A heterozygous truncating mutation in RRM2B causes autosomal-dominant progressive external ophthalmoplegia with multiple mtDNA deletions. PMID: 19664747
46. This study expands the clinical spectrum of impaired RIR2B function. PMID: 19667227
47. The X-ray crystal structure of human p53R2 is determined to 2.6 A, in which monomers A and B exhibit mono- and binuclear iron occupancy, respectively. Sequence-structure-function correlations that differentiate p53R2 and RRM2 are revealed. PMID: 19728742

Show More

Hide All

HGNC: 17296

OMIM: 604712

KEGG: hsa:50484

STRING: 9606.ENSP00000251810

UniGene: Hs.512592